Use of Closed-loop Anesthesia in Pediatric Patients (LoopPed)

This study has been terminated.
(difficulty in recruiting)
Information provided by (Responsible Party):
Hopital Foch Identifier:
First received: October 22, 2008
Last updated: September 10, 2013
Last verified: September 2013
To compare manual administration of propofol and remifentanil and dual closed-loop using bispectral index as the control variable during pediatric anesthesia

Condition Intervention Phase
Drug: Propofol
Drug: remifentanil
Drug: Remifentanil
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Target-Controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by the Index Bispectral: Comparison in Pediatric Patients Between Manual Perfusion and Automated Perfusion

Resource links provided by NLM:

Further study details as provided by Hopital Foch:

Primary Outcome Measures:
  • Percentage of time during which the bispectral index is between 40 and 60 [ Time Frame: anesthesia ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • propofol and remifentanil doses [ Time Frame: anesthesia ] [ Designated as safety issue: No ]

Enrollment: 45
Study Start Date: October 2008
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
closed-loop administration of propofol and remifentanil using bispectral index as the controller
Drug: Propofol
closed-loop administration using bispectral index as the controller
Drug: remifentanil
closed-loop administration using bispectral index as the controller
Active Comparator: 2
manual administration of propofol and remifentanil according to bispectral index values
Drug: Propofol
manual administration according bispectral index values
Drug: Remifentanil
manual administration according bispectral index values


Ages Eligible for Study:   6 Years to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • class ASA I, II or III
  • general anesthesia scheduled to last more than one hour
  • intraoperative hemorrhage planned to be less than 15% of the blood volume

Exclusion Criteria:

  • Combined general and regional anesthesia,
  • Patients with a pacemaker or scheduled for a cardiac or brain surgical procedure,
  • History of a neurological or a psychiatric disorder, or central brain lesion,
  • Patients receiving a psychotropic treatment or a a morphine agonist-antagonist,
  • Allergy to latex, propofol, remifentanil, morphine, muscle relaxant, or to a component,
  • Hypersensibility to remifentanil or to a derivate of fentanyl,
  • Scheduled postoperative ventilation or sedation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00778505

Hôpital Necker Enfants
Paris, France, 75015
Hôpital Foch
Suresnes, France, 92150
Sponsors and Collaborators
Hopital Foch
Study Chair: Marc Fischler, MD Hôpital Foch, Suresnes, France
  More Information

Responsible Party: Hopital Foch Identifier: NCT00778505     History of Changes
Other Study ID Numbers: 2008/21 
Study First Received: October 22, 2008
Last Updated: September 10, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Hopital Foch:

Additional relevant MeSH terms:
Analgesics, Opioid
Anesthetics, General
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Hypnotics and Sedatives
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on April 27, 2016